Skip to content

Aetion has entered into an agreement to be acquired by Datavant, a leading health data platform company.   Learn more → 

Evidence Hub

Jun 1, 2022

Measuring re-identification risk using a synthetic estimator to enable data sharing

Start Reading
May 25, 2022

Synthetic Data as a Privacy Enhancing Technology

Start Reading
May 19, 2022

Why work at a startup? Because everything you do matters

Several years ago, during a hiring interview for a software engineer position, the ...
Start Reading
May 18, 2022

Generating Synthetic Longitudinal Data

Start Reading
May 9, 2022

ISPOR Goes Real-World

Regulators, HTAs, and pharma leaders discuss RWE trends with Aetion experts.
Start Reading
Apr 27, 2022

Utility Assessments in Synthetic Data

Start Reading
Apr 19, 2022

RWE Guidance: NICE’s RWE Framework

This month, the UK’s National Institute for Health and Care Excellence (NICE) released ...
Start Reading
Apr 15, 2022

Utility Metrics for Evaluating Synthetic Health Data Generation Methods: Validation Study

Start Reading
Apr 8, 2022

Utility Metrics for Evaluating Synthetic Data Generation Methods

By Lucy Mosquera and Xi Fang Posted On: April 8, 2022 In order to work with synthetic ...
Start Reading
Mar 30, 2022

Managing and Regulating Privacy Risks in Synthetic Data

Start Reading
Mar 24, 2022

Blog post from CHEO Research Institute

By Replica Analytics staff Posted On: March 24th, 2022 This week, the CHEO Research ...
Start Reading
Mar 1, 2022

Synthetic Data Generation for Implementing the HIPAA Expert Determination Method

By Khaled El Emam Posted On: March 1st, 2022 The Expert Determination method is one of ...
Start Reading
Feb 17, 2022

Re-identification–the wrong criterion for synthetic data

By Khaled El Emam Posted On: February 17th, 2022
Start Reading
Feb 9, 2022

Synthetic Data Generation 101

Start Reading
Feb 9, 2022

Aetion’s comments to FDA on data standards for RWD in drug and biological product submissions

Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Start Reading
Feb 9, 2022

Speaking with Canadian legislators about anonymization

By Replica staff Posted On: February 9th, 2022
Start Reading
Feb 3, 2022

Aetion’s comments to FDA on electronic health records and claims to support regulatory decisions

Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Start Reading
Jan 28, 2022

Understanding propensity score weighting methods

Oftentimes researchers want to compare two medications—an existing medication to a newly ...
Start Reading
Jan 28, 2022

PETs protect privacy and enable data use and sharing for good

By Khaled El Emam Posted On: January 28th, 2022
Start Reading
Jan 24, 2022

Hot off the presses: Replica’s acquisition by Aetion generates coverage

By Replica Analytics staff Posted On: January 24th, 2022
Start Reading
Jan 13, 2022

A 2021 round-up of 10 articles, media and events about Replica and its solutions

By Replica Analytics staff Posted On: January 13th, 2022
Start Reading
Jan 4, 2022

Why we acquired synthetic data pioneer Replica Analytics

The potential for real-world evidence (RWE) to improve patient lives and better protect ...
Start Reading
Dec 22, 2021

What I learned from former FDA leaders during Aetion’s RWE Summit

Aetion hosted our annual RWE Summit in New York last month, and I am still inspired by ...
Start Reading
Dec 22, 2021

8 Really Good Reasons to Work at Replica Analytics

By Replica Analytics staff Posted On: December 22nd, 2021 At Replica Analytics, we’re ...
Start Reading